Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such…
Read the full story at The Guardian ↗
ImpactNotable
Published3 h ago (Tue, 10 Nov 2026 13:00:53 GMT)
AuthorJulia Kollewe
MoreLess
Impact score33/100
RatingRule-based estimate: no strong signals; trust 8/10.
RegionsUnited Kingdom
Retrievedvia rss
ClassifiedTue, 10 Nov 2026 14:02:44 GMT by heuristic